

# BH3 profiling as pharmacodynamic biomarker for the activity of BH3 mimetics

Rongqing Aaron Pan,<sup>1,2,3</sup> Youzhen Wang,<sup>4</sup> Shumei Qiu,<sup>4</sup> Mariana Villalobos-Ortiz,<sup>2,3</sup> Jeremy Ryan,<sup>2,3</sup> Erick Morris,<sup>4</sup> Ensar Halilovic<sup>4</sup> and Anthony Letai<sup>2,3</sup>

Correspondence:

A. LETAI - [anthony\\_letai@dfci.harvard.edu](mailto:anthony_letai@dfci.harvard.edu)

<https://doi.org/10.3324/haematol.2023.283060>

<sup>1</sup>Bone Marrow Transplantation Center of the First Affiliated Hospital & Institute of Hematology & Department of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China;

<sup>2</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; <sup>3</sup>Harvard Medical School, Boston, MA, USA and

<sup>4</sup>Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA

## Figure S1

- A) The genetic modifications and anti-apoptotic dependency of used cell lines.
  - B) Selectivity of used BH3 peptides and BH3 mimetics for BH3 profiling assays in this study.
  - C) Baseline mitochondrial priming of O\_BCL-2 and O\_MCL-1 cell lines, as determined by BH3 profiling (numbers following peptide names are used concentrations ( $\mu\text{M}$ ). DMSO negative control; ALM (alamethicin), positive control).
  - D) Five cell lines in Figure B were permeabilized with digitonin and incubated with BCL201 or S63845 for 45 min (mitochondrial exposure) and then examined for cytochrome c release.
  - E) Workflow of BH3 profiling of treated human PBMC (peripheral blood mononuclear cells) cells. Zombie Yellow (ZY) was used as the live/dead staining.
  - F) Gating strategy of human PBMC cells used for in vitro studies.
  - G) Diagram showing how delta priming is calculated.
- Data were presented as mean  $\pm$  SEM of triplicate experiments.

# Figure S1

